Medindia

X

PERK is a Crucial Contributor to Systemic and Neurodegenerative Disorders

by Dr. Trupti Shirole on  March 19, 2016 at 1:45 AM Research News   - G J E 4
While the impact of the endoplasmic reticulum (ER) kinase PERK in various systemic diseases has been well characterized, its involvement in neurodegeneration is established to a lesser extent.
 PERK is a Crucial Contributor to Systemic and Neurodegenerative Disorders
PERK is a Crucial Contributor to Systemic and Neurodegenerative Disorders
Advertisement

A major challenge in the field of neurodegeneration is the unclear understanding of neuronal dysfunction. Elucidation of these patho-mechanisms could result in the identification of novel therapeutic targets. In this article, Bell et al. present an exhaustive literature review highlighting PERK as a crucial contributor to systemic and neurodegenerative disorders.

‘PERK, and its downstream substrate eIF2, are pathologically, genetically, and molecularly linked to several neurodegenerative disorders.’
Advertisement
PERK, and its downstream substrate eIF2, are pathologically, genetically, and molecularly linked to several neurodegenerative disorders.

The active form of PERK, pPERK, is chronically upregulated in tauopathies such as Alzheimer's, Fronto-temporal dementia linked to chromosome 17, and Progressive Supranuclear Palsy (PSP). Genetically, a single nucleotide polymorphism in the gene coding for PERK, EIF2AK3, is associated with risk for PSP. Molecularly, pathogenic protein aggregates alter ER homeostasis triggering sustained PERK activation. Despite the reparative nature of its activity, long-term PERK activity activates pro-apoptotic cascades.

The objective of the review is to highlight the impact of PERK in neurodegenerative processes and underscore the pathway as a reservoir of therapeutic targets. To this end, current efforts attempting to inhibit PERK in in vivo models of tauopathy and prions have shown promising results. Therefore, PERK inhibition in these diseases is a promising therapeutic strategy, and efforts to develop optimal PERK inhibitors for the clinic are underway.

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All